FELDMAN H. A., GOLDSTEIN I., HATZICHRISTOU D. G. et al. Impotence and its medical and psychosocial correlates : results of the Massachusetts Male Aging Study. J Urol, 1994, 151: 54-61.
LAUMANN E. O., PAK A., ROSEN R. C. Sexual dysfunction in the United States : prevalence and predictors. JAMA, 1999, 281: 537-544. (Pubitemid 29081307)
BRAUN M., WASSNER G., KLOTZ T. et al. Epidemiology of erectile dysfunction : Results of the «Cologne male survey». Int J Impot Res, 2000,12:305-311.
GALIANO M., PIGNOT G., COSTA C., VALLANCIEN G., VIRAG R. Dysfunction erectile et cellules endotheliales caverneuses, en presse Progrès en Urologie 2010.
ROUMEGUERE T., WESPES E., CARPENTIER Y., HOFFMANN P., SCHULMAN C. C. Erectile dysfunction is associated with a high prevalence of hyperlipidemia and coronary heart disease risk. Eur Urol, 2003 ,44: 355-359. (Pubitemid 37051706)
MONTORSI P., MONTORSI F., SCHULMAN C. Is Erectile Dysfunction the "Tip of the Iceberg" of a Systemic Vascular Disorder ? Eur Urol, 2003,44 : 352-354.
SPEEL T. G., VANLANGEN H., MEULEMAN E. J. The risk of coronary heart disease in men with erectile dysfunction. Eur Urol, 2003,44 : 366-371. (Pubitemid 37051708)
THOMPSON I. M., TANGEN C. M., GOODMAN PH. J., PROBSTFLD J. L., MOINPOUR C. M., COLTMAN C. A. Erectile Dysfunction and Subsequent Cardiovascular Disease JAMA, 2005, 294: 2996-3002.
NEHRA A. Erectile dysfunction and cardiovascular disease : efficacy and safety of phosphodiesterase type 5 inhibitors in men with both conditions. Mayo Clin Proc, 2009, 84: 139-148.
SULLIVAN M. E., THOMPSON C. S., DASHWOOD M. R., KHAN M. A., JEREMY J. Y., MORGAN R. J., MIKHAIUDIS D. P. Nitric oxide and penile erection : Is erectile dysfunction another manifestation of vascular disease ? Cardiovascular Research, 1999, 43: 658-665.
ÜCKERT S., HEDLUNG P., ANDERSSON K. F., TRUSS M. C., JONAS U., JONAS U., STIEF C. G. Update on phosphodiesterase (PDE) isoenzymes as pharmacologic targets in urology : present and future. Eur Urol, 2006, 50: 1194-1207.
ANDRIANNE R., D'ORIO V. Consensus on the clinical approach to erectile dysfunction in patients with cardiovascular disease. Rev Med Liege, 2000, 55 :454-458. (Pubitemid 30484721)
PERIMENIS P., ATHANASOPOULOS A., GYFTOPOULOS K., BARBALIAS G. Sildenafil test : changes in the diagnostic and therapeutic management of erectile dysfunction. Int Urol Nephrol, 2001, 33:387-389. (Pubitemid 34575396)
HATZICHRISTOU D., HARZIMOURATIDIS K., BEKAS M., APOSTOUDIS A., TZORTZIS V., YANNAKOYORGOS K. Diagnostic steps in the evaluation of patients with erectile dysfunction. J Urol, 2002,168 : 615-620. (Pubitemid 34793308)
SALTZMAN E. A., GUAY A. T., JACBSON J. Improvement in erectile function in men with organic erectile dysfunction by correction of elevated cholesterol levels : a clinical observation. J Urol, 2004, 172:255-258.
CARO J. L. L. Sexual Dysfunction in Hypertensive Patients Treated with Losartan. Am J Med Sci, 2001, 321: 336-341 (Pubitemid 32428834)
DERBY C. A., MOHR B. A., GOLDSTEIN I. et al. Modifiable risk factors and erectile dysfunction : can lifestyle changes modify risk ? Urology, 2000, 56 : 302-306.
SOMMER F., SCHULZE W. Treating erectile dysfunction by endothelial rehabilitation with phosphodiesterase 5 inhibitors World J Urol, 2005, 23 : 385-392. (Pubitemid 43124389)
ROSANO G. M. C., AVERSA A., VITALE C., FABBRI A., FINI M., SPERA G. Chronic treatment with tadalafil improves endothelial function in men with increased cardiovascular risk. Eur Urol, 2005,47: 214-220.
RADOVITS T., BÖMICKE T., KÖKÉNY G., ARIF R., LOGANATHAN S., KÉCSÁN K., KORKMAZ S., BARNUCZ E., SANDNER P., KARCK M., SZABÓ G. The phosphodiesterase-5 inhibitor vardenafil improves cardiovascular dysfunction in experimental diabetes mellitus. Br J Pharmacol, 2009, 156 : 909-919.
OPSOMER R. J., WESE F. X., VAN CANGH P. J. Long-term results with vacuum constriction device. Proceedings of the 8th World Meeting on Impotence Research, Monduzzi Editore, International Proceedings Division, Bologna, It., 1998, pp. 271-274.
ANDRIANNE R, BALDE S, DE LEVAL J, KEMPENERS P, MORMONT C. La prothèse pénienne en cas d'impuissance : 12 ans d'expérience. Acta Urol Belg, 1995, 63 : 89-96.
bis. LEGROS J. J., FRANCHIMONT P., PALEM M. FSH, LH and Testosterone blood levels in patients with psychogenic impotency. Endocrinol Experim, 1973,7 : 59-63.
BUVAT J., Bou JAOUDÉ G. Significance of hypogonadism in erectile dysfunction. World J Urol, 2006, 24 : 657-667.
EARLE C. M., STUCKEY B. G. Biochemical screening in the assessment of erectile dysfunction : what tests decide future therapy ? Urology, 2003, 62: 727-731.
JANNINI E. A., SCREPONI E., CAROSA E. et al. Lack of sexual activity from erectile dysfunction is associated with a reversible reduction in serum testosterone. Int J Androl, 1999, 22 : 385-392.
KIM Y.C., BUVAT J., CARSON C. C., GOOREN L. J., JAROW J., RAIFER J., VERMEULEN A. Endocrine and metabolic aspects including treatment. In : JARDIN A., WAGNER G., KHOURY S., GIULIANO F., PADMA-NATHAN H., ROSEN R. Erectile Dysfunction. Proceedings of the First International Consultation on Erectile Dysfunction, Paris, Plymbridge, Plymouth, UK, 1999, pp 205-240
MORALES A., JOHNSON B., HEATON J. W., CLARK A. Oral androgens in the treatment of hypogonadal impotent men. J Urol, 1994, 152 : 1115-1118.
MORALES A., JOHNSTON B., HEATON J. P. W., LUNDIE M. Testosterone supplementation for hypogonadal impotence : assessment of biochemical measures and therapeutic outcomes. J Urol, 1997, 157 : 849-854.
WYLIE K, DAVIES-SOUTH D. A study of treatment choices in men with erectile dysfunction and reduced androgen levels. J Sex and Mar Ther, 2004, 30: 107-114.
BUVAT J., LEMAIRE A. Endocrine screening in 1022 men with erectile dysfunction : clinical significance and cost-effective strategy. J Urol, 1997, 158: 764-767.
CAROSA E, MARTINI P, BRANDETTI F. et al Type V phosphodiesterase inhibitor treatments for erectile dysfunction increase testosterone levels. Clin Endocrinol (Oxf), 2004, 61: 382-386. (Pubitemid 39287069)
ANDRIANNE R., CHABOT C. Penile prosthesis implantation increases total testosterone level. J Sex Res, 2008, 45: 90-117.
JAOUDÉ G. B., BUVAT J. Déficit en Testostérone et Dysfonction Erectile Communication Société Française de Sexologie (SFS).
SCHLEICH F., LEGROS J. J. Effects of androgen substitition on lipid profile in adult and ageing hypogonadal male. Europ J Endocrinol, 2004 , 151:415-424.
SMEETS L, LEGROS J. J. Cœur et androgenes. Rev Med Lg, 2004, 59 : 439-1434
WANG C., NIESCHLAG E., SWERDLOFF R., BEHRE H. M., HELLSTROM W. J., GOOREN L. J., KAUFMAN J. M., LEGROS J. J., LUNENFELD B., MORALES A., MORLEY J. E., SCHULMANN C., THOMPSON I. M., WEIDNER W., WU F. C. Investigation, treaunent and monitoring of late-onset hypogonadism in males. Int J Androl, 2009, 32: 1-10.
CAMINITI G., VOLTERRANI M., IELLAMO F., MARAZZI G., MASSARO R., MICEU M., MAMMI C., MASSIMO P., FINI M., ROSANO G. Effect of long-acting Testosterone treatment on fonctionnal exercise capacity ,skeletal muscle performance, insulin resistance and baroreflex sensitivity in elderly patient with congestive heart failure. J Am Coll Cardiol, 2009, 54:919-927.
SHABSIGH R., ARVER S., CHANNER K. S., EARDLEY I., GOOREN L., HEUFELDER A., JONES H., MERYN S., ZITSMANN M. The triad of erctile dysfunction, hypogonadism and the metabolic syndrome. Int J Clin Pract, 2008, 62 : 791-798. (Pubitemid 351533668)
